Alain Moussy, AB Science
Clinical studies for AB Science's all-purpose anti-inflammatory drug grind to a halt as company flags potential risk of heart disease
When AB Science claimed a breakout win in Alzheimer’s disease for masitinib, its all-purpose tyrosine kinase inhibitor, in late December, CEO Alain Moussy pointed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
